Methods and compositions for the selective modification of nucleic
OwnerEdward I. Budowsky, Samuel K. Ackerman +2inventors
InventorsEdward I. Budowsky, Samuel K. Ackerman, Andrei A. Purmal, Clark M. Edson
Life of this patent
Estimating the term…
Abstract
Methods and compositions for selectively modifying nucleic acid molecules in biological compositions, including contacting the composition with an inactivating agent having the formula: 1 where each of R1, R2, R3, R4, R6, R7, and R8 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that R1, R2, R3, R4, R6, R7, and R8 cannot all be H; R5 is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive; X is a pharmaceutically acceptable counter-ion; and n is an integer between 2 and 10, inclusive are disclosed.
Claims60
A method of selectively modifying nucleic acid molecules in a biological composition, said method comprising the step of contacting the composition with an inactivating agent having the formula:
- 12
- wherein each of R1, R2, R3, R4, R6, R7, and R8 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that R1, R2, R3, R4, R6, R7, and R8 cannot all be H;
- R5 is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive;
- X is a pharmaceutically acceptable counter-ion;
- and n is an integer between 2 and 10, inclusive.
A killed vaccine comprising an effective amount of inactivated vertebrate virus and a pharmaceutically acceptable carrier, wherein said inactivated vertebrate virus is made by a process of incubating said virus with an inactivating agent under viral inactivating conditions, wherein said inactivating agent has the formula:
- 13
- wherein each of R1, R2, R3, R4, R6, R7, and R8 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that R1, R2, R3, R4, R6, R7, and R8 cannot all be H;
- R5 is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive;
- X is a pharmaceutically acceptable counter-ion;
- and n is an integer between 2 and 10, inclusive.
A blood-collecting device comprising a container for receiving blood or a blood fraction, the container comprising an inactivating agent in an amount effective to inactivate viruses in the blood or fraction thereof received into the container, wherein the inactivating agent has the formula:
- 14
- wherein each of R1, R2, R3, R4, R6, R7, and R8 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that R1, R2, R3, R4, R6, R7, and R8 cannot all be H;
- R5 is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive;
- X is a pharmaceutically acceptable counter-ion;
- and n is an integer between 2 and 10, inclusive.
A method of selectively modifying nucleic acid molecules in a biological composition, said method comprising the step of contacting the composition with an inactivating agent having the formula:
- ω—X1—[R1—N+(R2, R3)—]nR4′(X2−)n
- wherein X1 is Cl or Br;
- R1 is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive;
- each of R2, R3, and R4 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that R2, R3, and R4 cannot all be H when R1 contains 2 carbon atoms;
- X2 is a pharmaceutically acceptable counter-ion;
- and n is an integer between 2 and 10, inclusive.
A killed vaccine comprising an effective amount of inactivated vertebrate virus and a pharmaceutically acceptable carrier, wherein said inactivated vertebrate virus is made by a process of incubating said virus with an inactivating agent under viral inactivating conditions, wherein said inactivating agent has the formula:
- ω—X1—[R1—N+(R2, R3)—]nR4′(X2−)n
- wherein X1 is Cl or Br;
- R1 is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive;
- each of R2, R3, and R4 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that R2, R3, and R4 cannot all be H when R1 contains 2 carbon atoms;
- X2 is a pharmaceutically acceptable counter-ion;
- and n is an integer between 2 and 10, inclusive.
A blood-collecting device comprising a container for receiving blood or a blood fraction, the container comprising an inactivating agent in an amount effective to inactivate viruses in the blood or fraction thereof received into the container, wherein the inactivating agent has the formula:
- ω—X1—[R1—N+(R2, R3)—]nR4′(X2−)n
- wherein X1 is Cl or Br;
- R1 is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive;
- each of R2, R3, and R4 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that R2, R3, and R4 cannot all be H-when R1 contains 2 carbon atoms;
- X2 is a pharmaceutically acceptable counter-ion;
- and n is an integer between 2 and 10, inclusive.
A nucleic acid inactivating agent having the formula:
- ω—X1—[R1—N+(R2, R3)—]nR4′(X2−)n
- wherein X1 is Cl or Br;
- R1 is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive;
- each of R2, R3, and R4 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that R2, R3, and R4 cannot all be H when R1 contains 2 carbon atoms;
- X2 is a pharmaceutically acceptable counter-ion;
- and n is an integer between 2 and 10, inclusive.
A method of selectively modifying nucleic acid molecules in a biological composition, said method comprising the step of contacting the composition with an inactivating agent having the formula:
- β—X1—CH2CH2—N+H(R1)—[R2—N+(R3, R4)—]nR5′(X2−)n+1
- wherein X1 is Cl or Br;
- each of R1, R3, R4, and R5 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive;
- R2 is a divalent hydrocarbon moiety containing 3 or 4 carbon atoms;
- X2 is a pharmaceutically acceptable counter-ion;
- and n is an integer between 2 and 10, inclusive.
A killed vaccine comprising an effective amount of inactivated vertebrate virus and a pharmaceutically acceptable carrier, wherein said inactivated vertebrate virus is made by a process of incubating said virus with an inactivating agent under viral inactivating conditions, wherein said inactivating agent has the formula:
- β—X1—CH2CH2—N+H(R1)—[R2—N+(R3, R4)—]nR5′(X2−)n+1
- wherein X1 is Cl or Br;
- each of R1, R3, R4, and R5 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive;
- R2 is a divalent hydrocarbon moiety containing 3 or 4 carbon atoms;
- X2 is a pharmaceutically acceptable counter-ion;
- and n is an integer between 2 and 10, inclusive.
A blood-collecting device comprising a container for receiving blood or a blood fraction, the container comprising an inactivating agent in an amount effective to inactivate viruses in the blood or fraction thereof received into the container, wherein the inactivating agent has the formula:
- β—X1—CH2CH2—N+H(R1)—[R2—N+(R3, R4)—]nR5′(X2−)n+1
- wherein X1 is Cl or Br;
- each of R1, R3, R4, and R5 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive;
- R2 is a divalent hydrocarbon moiety containing 3 or 4 carbon atoms;
- X2 is a pharmaceutically acceptable counter-ion;
- and n is an integer between 2 and 10, inclusive.
A nucleic acid inactivating agent having the formula:
- β—X1—CH2CH2—N+H(R1)—[R2—N+(R3, R4)—]nR5′(X2−)n+1
- wherein X1 is Cl or Br;
- each of R1, R3, R4, and R5 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive;
- R2 is a divalent hydrocarbon moiety containing 3 or 4 carbon atoms;
- X2 is a pharmaceutically acceptable counter-ion;
- and n is an integer between 2 and 10, inclusive.
Dependencies are inferred from the claim text.